Vitae's Vagueness On Psoriasis Program Spooks Investors
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision to end enrollment prematurely of Phase IIa proof-of-concept study apparently has led investors to assume safety issues for the first-in-class ROR gamma T inhibitor.
You may also be interested in...
Could $639m Vitae Buy Give Allergan A New Autoimmune Focus?
Allergan’s $639m purchase of Vitae Pharmaceuticals gives the company an oral drug for a key dermatology indication and the potential to address other autoimmune disorders consistent with its focus on seven key therapeutic areas.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.